000307526 001__ 307526
000307526 005__ 20260126103124.0
000307526 0247_ $$2doi$$a10.1016/j.dld.2025.12.002
000307526 0247_ $$2pmid$$apmid:41484031
000307526 0247_ $$2ISSN$$a1590-8658
000307526 0247_ $$2ISSN$$a1878-3562
000307526 037__ $$aDKFZ-2026-00031
000307526 041__ $$aEnglish
000307526 082__ $$a610
000307526 1001_ $$aVavallo, Marica$$b0
000307526 245__ $$aHelicobacter pylori multiplex serology in patients with autoimmune atrophic gastritis negative for Helicobacter pylori at histology: A case-control study.
000307526 260__ $$a[Erscheinungsort nicht ermittelbar]$$bSaunders$$c2026
000307526 3367_ $$2DRIVER$$aarticle
000307526 3367_ $$2DataCite$$aOutput Types/Journal article
000307526 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1769419844_3933356
000307526 3367_ $$2BibTeX$$aARTICLE
000307526 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000307526 3367_ $$00$$2EndNote$$aJournal Article
000307526 500__ $$a2026 Feb;58(2):212-219
000307526 520__ $$aAutoimmune atrophic gastritis (AAG) is an immune-mediated disorder affecting the gastric oxyntic mucosa. Two pathogenetic models are proposed: a pure autoimmune disorder or gastric autoimmunity triggered by Helicobacter pylori (Hp)-infection. In AAG, histological diagnosis of Hp may be challenging and serology can help assess exposure to Hp-infection. This study aimed to determine seroreactivity to Hp-antigens in AAG patients by using Hp-multiplex serology assay.A single-centre case-control study on 178 adults: 75 patients with serological and histological AAG diagnosis, 25 controls with histologically Hp-positive-non-atrophic gastritis (Ctr-NAG-Hp+) and 78 subjects with a healthy stomach (Ctr-HS). Sera were analysed using Hp-multiplex serology assay allowing simultaneous detection of antibodies to 13 Hp-proteins. Overall positivity cutoff: seroreactivity to more than 3 Hp-antigens.The number of seroreactive Hp-antigens was higher in AAG than in Ctr-HS(mean±SEM 2.2±0.3 vs 1.4±0.22,p=0.02) and lower than in Ctr-NAG-Hp+ patients (mean±SEM 5.4±0.5,p<0.001).Overall Hp-seropositivity in AAG was two-fold higher than in Ctr-HS but not statistically significant (21.1% vs 10.3%,p=0.06) and lower than in Ctr-NAG-Hp+(80%,p<0.0001). Complete absence of seroreactivity was similar in AAG and Ctr-HS (29.3% vs 38.5%, p=0.23) and significantly higher than in Ctr-NAG-Hp+ (4%, p=0.009). Main immunogenic Hp-proteins were HP0010(GroEL),HP1098(HcpC),HP0695(HyuA),HP0875(Catalase),HP1564,HP0547(CagA) and HP0243(NapA) with seroreactivity in >50% of AAG patients.By Hp-multiplex serology, 30% of histologically Hp-negative AAG pts had no seroreactivity, likely belonging to the pure AAG type. Conversely, 20% of AAG pts showed Hp exposure, indicating that infection might have triggered gastric autoimmunity. The remaining AAG patients showed seroreactivity below cut-off for seropositivity and thus not definitively categorisable by this approach.
000307526 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000307526 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000307526 650_7 $$2Other$$aAtrophic gastritis
000307526 650_7 $$2Other$$aAutoimmune gastritis
000307526 650_7 $$2Other$$aHelicobacter pylori
000307526 650_7 $$2Other$$aMultiplex serology
000307526 7001_ $$0P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aButt, Julia$$b1$$udkfz
000307526 7001_ $$aCingolani, Sophia$$b2
000307526 7001_ $$aCozza, Giulio$$b3
000307526 7001_ $$aSchiavone, Francesco Paolo$$b4
000307526 7001_ $$aDilaghi, Emanuele$$b5
000307526 7001_ $$aBelloni, Laura$$b6
000307526 7001_ $$aFranchitto, Matteo$$b7
000307526 7001_ $$aAnnibale, Bruno$$b8
000307526 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b9$$udkfz
000307526 7001_ $$aLahner, Edith$$b10
000307526 773__ $$0PERI:(DE-600)2061359-3$$a10.1016/j.dld.2025.12.002$$gp. S1590865825012289$$n2$$p212-219$$tDigestive and liver disease$$v58$$x1590-8658$$y2026
000307526 909CO $$ooai:inrepo02.dkfz.de:307526$$pVDB
000307526 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000307526 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000307526 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000307526 9141_ $$y2026
000307526 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-05
000307526 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-05
000307526 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-05
000307526 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-05
000307526 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-05
000307526 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-05
000307526 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-05
000307526 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-05
000307526 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-05
000307526 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bDIGEST LIVER DIS : 2022$$d2024-12-05
000307526 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-05
000307526 9201_ $$0I:(DE-He78)C230-20160331$$kC230$$lInfektionen und Krebsepidemiologie$$x0
000307526 980__ $$ajournal
000307526 980__ $$aVDB
000307526 980__ $$aI:(DE-He78)C230-20160331
000307526 980__ $$aUNRESTRICTED